GlucoBoost - Glucose Gel - Pack of 3

Product Information

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme. Dilution or addition to parenteral nutrition admixtures must take place in controlled and validated aseptic conditions. As with the intravenous administration of nutrients (e.g., glucose, amino acids and lipids) in general, metabolic complications may occur if the nutrient intake is not adapted to the patient's requirements, or the metabolic capacity of any given dietary component is not accurately assessed. Adverse metabolic effects may arise from administration of inadequate or excessive nutrients or from inappropriate composition of an admixture for a particular patient's needs. Careful symptomatic and laboratory monitoring for fever/chills, leukocytosis, technical complications with the access device, and hyperglycaemia can help recognize early infections. Do not use plastic containers in series connections. Such use could result in air embolism due to residual air being drawn from the primary container before the administration of the fluid from the secondary container is completed.

Notify Paediatrician immediately for all babies who are symptomatic or whose blood Glucose is <1.0mmol/l Babies who cannot tolerate enteral feeds or whose blood glucose remains <2.6mmol/l despite frequent NG feeds ( as above) OR who become symptomatic GlucoBoost Glucose Gel from Ennogen Healthcare is a 40% Glucose Oral Gel that is widely used in the NHS. If the blood glucose level is still 3.9mmol/l or below when you re-test repeat administration of Glucogel and re-test in another 15 minutes.

Additives known or determined to be incompatible with glucose as a diluent should not be used. The instructions for use of the medication to be added, including information on storage, must be consulted.

Before adding a substance or medication, verify that it is soluble and/or stable in water and that the pH range of the glucose solution is appropriate. Use of a vented intravenous administration set with the vent in the open position could result in air embolism. Vented intravenous administration sets with the vent in the open position should not be used with flexible plastic containers.When Glucose 40% w/v is used in conjunction with amino acids, the rate of administration of glucose should not exceed 1g/kg/hour for optimal protein anabolism.

If signs of pulmonary distress occur, the infusion should be stopped and medical evaluation initiated. Hypersensitivity/infusion reactions, including anaphylactic/anaphylactoid reactions, have been reported (see section 4.8). The occurrence of septic complications can be decreased with heightened emphasis on aseptic technique in catheter placement, maintenance, as well as aseptic technique in nutritional formula preparation. Particular caution is advised in patients at increased risk of water and electrolyte disturbances that could be aggravated by increased free water load, hyperglycaemia or possibly required insulin administration (see below). Discontinue monitoring when blood glucose concentrations have been > 2.5mmol/l on three consecutive occasions at least 3 hours apart. Observe feeding in hospital for at least a further 24 hours ensuring it is effective while remaining vigilant for the signs of hypoglycaemia. If signs of hypoglycaemia develop or there are concerns about feeding discuss with medical staff and consider taking a further blood glucose.The infusion rate and volume depends on the age, weight, clinical and metabolic conditions of the patient, concomitant therapy and should be determined by the consulting physician experienced in paediatric intravenous fluid therapy (see section 4.4). Identify all late preterm babies at birth and commence a hypoglycaemia/NEWS monitoring chart in labour ward. All babies should be risk assessed for criteria for hypoglycaemia monitoring and/or NEWS monitoring prior to leaving a labour ward environment Patient placed in the recovery position to ensure a clear airway for adequate breathing and to prevent inhalation of vomit.

thiamine deficiency, e.g., in patients with chronic alcoholism (risk of severe lactic acidosis due to impaired oxidative metabolisation of pyruvate), The resultant admixture should be administered through a central or peripheral venous line depending on its final osmolarity. If the final mixture, to be administered, is hypertonic it may cause irritation of the vein when administered into a peripheral vein.avoid infusion within the first 24 hours following head trauma. Monitor blood glucose closely as early hyperglycaemia has been associated with poor outcomes in patients with severe traumatic brain injury. Enteral feeds may continue initially but if hypoglycaemia persists despite increasing volumes of IV Glucose then a temporary cessation of enteral feeds may be required.